Vincent Zimmern

Dr. Vincent Zimmern

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in Frontiers in Neural Circuits
Verified
Journal Article
Open access
PDF file
VZVincent Zimmern
Vincent Zimmern
The past 25 years have seen a strong increase in the number of publications related to criticality in different areas of neuroscience. The potential of criticality to explain various brain properties, including optimal information processing, has made it an increasingly exciting area of investigation for neuroscientists. Recent reviews on this topic, sometimes termed brain criticality, make brief mention of clinical applications of these findings to several neurological disorders such as epilepsy, neurodegenerative disease, and neonatal hypoxia. Other clinicallyrelevant domains – including anesthesia, sleep medicine, developmental-behavioral pediatrics, and psychiatry – are seldom discussed in review papers of brain criticality. Thorough assessments of these application areas and their relevance for clinicians have also yet to be published. In this scoping review, studies of brain criticality involving human data of all ages are evaluated for their current and future clinical relevance. To make the results of these studies understandable to a more clinical audience, a review of the key concepts behind criticality (e.g., phase transitions, long-range temporal correlation, self-organized criticality, power laws, branching processes) precedes the discussion of human clinical studies. Open questions and forthcoming areas of investigation are also considered.

27 January 2024 in Genes
Verified
Journal Article
Open access
PDF file
VZVincent Zimmern
Vincent Zimmern
BMBerge A. Minassian
Berge A. Minassian
The progressive myoclonus epilepsies (PME) are a diverse group of disorders that feature both myoclonus and seizures that worsen gradually over a variable timeframe. While each of the disorders is individually rare, they collectively make up a non-trivial portion of the complex epilepsy and myoclonus cases that are seen in tertiary care centers. The last decade has seen substantial progress in our understanding of the pathophysiology, diagnosis, prognosis, and, in select disorders, therapies of these diseases. In this scoping review, we examine English language publications from the past decade that address diagnostic, phenotypic, and therapeutic advances in all PMEs. We then highlight the major lessons that have been learned and point out avenues for future investigation that seem promising.

17 February 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
VZVincent Zimmern
Vincent Zimmern
BMBerge Minassian
Berge Minassian
CKChristian Korff
Christian Korff
Genetic sequencing technologies have led to an increase in the identification and characterization of monogenic epilepsy syndromes. This increase has, in turn, generated strong interest in developing “precision therapies” based on the unique molecular genetics of a given monogenic epilepsy syndrome. These therapies include diets, vitamins, cell-signaling regulators, ion channel modulators, repurposed medications, molecular chaperones, and gene therapies. In this review, we evaluate these therapies from the perspective of their clinical validity and discuss the future of these therapies for individual syndromes.

25 March 2019 in Biometrical Journal
Verified
Journal Article
Closed access
PDF file
FAFolefac D. Atem
Folefac D. Atem
RMRoland A. Matsouaka
Roland A. Matsouaka
VZVincent Zimmern
Vincent Zimmern

21 June 2019 in Neuropediatrics
Verified
Journal Article
Closed access
PDF file
VZVincent Zimmern
Vincent Zimmern
FRFlorence Riant
Florence Riant
EREmmanuel Roze
Emmanuel Roze
EREmmanuelle Ranza
Emmanuelle Ranza
FLFrank Lehmann-Horn
Frank Lehmann-Horn
CKChristian M Korff
Christian M Korff
Mutations that disrupt the TBC1D24 presynaptic protein have been implicated in various neurological disorders including epilepsy, chronic encephalopathy, DOORS (deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures) syndrome, nonsyndromic hearing loss, and myoclonus. We present the case of a 22-month-old male with infantile-onset paroxysmal episodes of facial and limb myoclonus. The episodes were linked to biallelic variants in exon 2 of the TBC1D24 gene that lead to amino acid changes (c.304C >T/p.Pro102Ser and c.410T > C/p.Val137Ala), each variant being inherited from a parent. Follow-up imaging in adolescence revealed widened right cerebellar sulci. We discuss the evolving landscape of TBC1D24 associated phenotypes; this case adds to a growing body of evidence linking this gene to movement disorders in children.